Home » Stocks » MDGL

Madrigal Pharmaceuticals, Inc. (MDGL)

Stock Price: $88.72 USD 3.15 (3.68%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
Market Cap 1.44B
Revenue (ttm) n/a
Net Income (ttm) -218.66M
Shares Out 15.84M
EPS (ttm) -14.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $88.72
Previous Close $85.57
Change ($) 3.15
Change (%) 3.68%
Day's Open 86.02
Day's Range 85.58 - 88.88
Day's Volume 126,511
52-Week Range 83.71 - 142.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Madrigal (MDGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co...

1 day ago - Zacks Investment Research

CONSHOHOCKEN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension study...

2 weeks ago - GlobeNewsWire

CONSHOHOCKEN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today achievement of the planned target enrollment in the Phase 3 clinical trial, MAESTRO-NASH...

4 weeks ago - GlobeNewsWire

CONSHOHOCKEN, Pa., June 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), today announced the presentation of positive clinical data from the open-label portion of its ongoing P...

1 month ago - GlobeNewsWire

WEST CONSHOHOCKEN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and f...

1 month ago - GlobeNewsWire

WEST CONSHOHOCKEN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fat...

2 months ago - GlobeNewsWire

WEST CONSHOHOCKEN, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fat...

2 months ago - GlobeNewsWire

WEST CONSHOHOCKEN, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first quarter 2021 financial results and highlights.

2 months ago - GlobeNewsWire

This pharma may be a newcomer to the stock market, but it has several innovative drugs in development for a common condition with no current treatments approved.

Other stocks mentioned: GILD, ICPT, NVS, PFE, TERN
4 months ago - The Motley Fool

WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights.

5 months ago - GlobeNewsWire

Reddit playing a major role in biotech trading action, says Jefferies top health care analyst

YouTube video

Jared Holz, Jefferies managing director and healthcare sector specialist, on which biotech stocks could be the next targets. With Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen Fi...

Other stocks mentioned: KPTI, RCKT
5 months ago - CNBC Television

The GameStop effect will soon come to biopharma, an usually heavily-shorted sector. Here's a list of three of biopharma's more heavily-shorted stocks.

Other stocks mentioned: LGND, NKTR
5 months ago - Seeking Alpha

In November, Madrigal released open label data from the MAESTRO-NAFLD study. This data was positive, and could be used to make predictions about the entire study.

8 months ago - Seeking Alpha

CONSHOHOCKEN, Pa., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), announced that Dr. Stephen Harrison, M.D., Medical Director for Pinnacle Clinical Research, San Antonio...

8 months ago - GlobeNewsWire

CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in pati...

8 months ago - GlobeNewsWire

When it comes to extreme wealth creation, few endeavors can compare to being an owner of a small-cap stock that grows large. The post Small-Cap Stocks Have Led Every Bull Market for Decades appeared fir...

Other stocks mentioned: AXSM, NKLA, TLRY
9 months ago - InvestorPlace

CONSHOHOCKEN, Pa., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), announced today that, based on data from studies with MGL-3196 (resmetirom), three posters and an oral ...

9 months ago - GlobeNewsWire

CONSHOHOCKEN, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it has already exceeded the originally targeted enrollment of 700 patients in it...

10 months ago - GlobeNewsWire

CONSHOHOCKEN, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™ 2020, Eur...

11 months ago - GlobeNewsWire

CONSHOHOCKEN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights:

11 months ago - GlobeNewsWire

These two companies are going after the same target, but which one should you bet on today?

Other stocks mentioned: ICPT
1 year ago - The Motley Fool

Madrigal Pharmaceuticals sees its Relative Strength Rating enter the 80-plus level. The post Madrigal Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating appeared first on Investor's Busines...

1 year ago - Investors Business Daily

They have one big thing in common: great growth prospects.

Other stocks mentioned: BMY, VRTX
1 year ago - The Motley Fool

Madrigal's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: IVC, MRNA
1 year ago - Seeking Alpha

-- MAESTRO Phase 3 clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to maintain patient safety a...

1 year ago - GlobeNewsWire

Madrigal: A Stellar Stock For This Coronavirus Bear Market

1 year ago - Seeking Alpha

The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belongs to Inte...

Other stocks mentioned: BMY, GNFT, ICPT, NVS, PTCT, RHHBY
1 year ago - GuruFocus

These companies are developing drugs that target the one of the biggest threats from the obesity epidemic.

Other stocks mentioned: ICPT
1 year ago - The Motley Fool

Impressive cash position.

1 year ago - Seeking Alpha

Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) has seen more than its share of volatility over the past year.

1 year ago - 24/7 Wall Street

Madrigal: Beyond NASH

1 year ago - Seeking Alpha

-- MAESTRO-NAFLD-1 is the second resmetirom Phase 3 clinical trial in patients with NASH and presumed NASH and follows MAESTRO-NASH, a Phase 3 multi-center, double-blind, randomized, placebo-controlled ...

1 year ago - GlobeNewsWire

WEST CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the develop...

1 year ago - GlobeNewsWire

CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the development ...

1 year ago - GlobeNewsWire

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Other stocks mentioned: AGN, CBAY, CNAT, GLMD, ICPT
1 year ago - Zacks Investment Research

Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH:

1 year ago - GlobeNewsWire

CONSHOHOCKEN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights:

1 year ago - GlobeNewsWire

Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.

Other stocks mentioned: ASMB, CBAY
1 year ago - The Motley Fool

Which of these NASH-oriented biotechs is the better buy?

Other stocks mentioned: ICPT
1 year ago - The Motley Fool

Madrigal is one of the more prominent NASH-targeted biopharma companies today.

1 year ago - Seeking Alpha

The following securities are falling knives, meaning their share prices have declined more than 59% over the last 52 weeks.

Other stocks mentioned: INGN
2 years ago - GuruFocus

Biotech stocks Intercept Pharmaceuticals and Madrigal Pharmaceuticals were hit Thursday after the Food and Drug Administration cast doubt on a method of evaluating some liver disease drugs.

Other stocks mentioned: ICPT
2 years ago - Investors Business Daily

Medical technology and biotech stocks were ravaged Wednesday on a "Medicare for All" proposal out of Washington and amid rising popularity for presidential candidate Bernie Sanders.

Other stocks mentioned: DXCM, IONS, ISRG, MASI
2 years ago - Investors Business Daily

Although possessing huge market opportunities, there is currently no ideal NASH candidate in the late clinical stage.

2 years ago - Seeking Alpha

Liver Therapy Forum weekly digest provides an overview on what’s happening in the NASH landscape in 2019. This week focuses on Madrigal.

2 years ago - Seeking Alpha

About MDGL

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquar... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
Rebecca Taub
Employees
42
Stock Exchange
NASDAQ
Ticker Symbol
MDGL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 16 analysts, the average rating for MDGL stock is "Buy." The 12-month stock price forecast is 177.77, which is an increase of 100.37% from the latest price.

Price Target
$177.77
(100.37% upside)
Analyst Consensus: Buy